Zevra Revenue Jumps 486 Percent in Q2

Zevra Therapeutics reported Q2 2025 GAAP revenue of $25.9 million, exceeding estimates due to strong MIPLYFFA sales, and swung to a GAAP net income of $74.7 million, primarily driven by a one-off $150 million priority review voucher (PRV) sale. This one-time event masked underlying operational challenges, as the poor performance of OLPRUVA led to a $58.7 million impairment and an $11.7 million inventory write-down, underscoring the inherent risks in rare disease drug commercialization and indicating that core profitability remains elusive without such extraordinary items.

Analysis

Zevra Therapeutics reported a mixed Q2 2025, with headline figures masking significant underlying operational challenges. While GAAP revenue of $25.9 million surpassed estimates by 14.8% and the company swung to a GAAP net income of $74.7 million, this profitability was entirely attributable to a one-time $150 million sale of a Priority Review Voucher (PRV). The core business remains unprofitable. The company's primary growth asset, MIPLYFFA, generated $21.5 million in revenue and saw U.S. market access expand to 52% of covered lives. However, its momentum is showing signs of strain, as new prescription enrollments decelerated to 7 in Q2 from 13 in Q1, a concerning trend given the small, finite patient pool. In a stark contrast, the commercial launch of OLPRUVA has effectively failed, contributing negligible revenue ($0.3 million) and forcing the company to record a $58.7 million non-cash impairment and an $11.7 million inventory write-down due to persistently low demand. Further pipeline risk is evident in the slow enrollment for the celiprolol Phase 3 trial. While the PRV sale fortified the balance sheet with $217.7 million in cash, providing a crucial operational runway, the lack of quantitative guidance for fiscal 2025 underscores the uncertainty surrounding the company's path to sustainable, organic growth.

Key Decisions for Investors

• Investors should normalize Q2 results by excluding the one-time $150 million PRV sale and the OLPRUVA impairment charge to accurately assess the company's underlying operational performance and cash burn rate.
• Closely monitor MIPLYFFA's new patient enrollment rate in subsequent quarters, as the Q2 deceleration is a critical risk to the company's primary growth driver and overall valuation.
• Scrutinize management's forthcoming strategy for the OLPRUVA asset, as its commercial failure represents a significant setback and a material destruction of previously invested capital.
• Acknowledge that the strong cash position of $217.7 million provides a significant buffer against near-term financing needs, but this does not mitigate the commercial and clinical risks facing the product portfolio.